For decades, scientists have looked for correlates for schizophrenia in the brain. The ultimate hope is that clinicians can use the biological information of a given individual to prevent illness onset and progression, develop new treatments, or use personalise already available treatments.
In this video, Dr. Jose M. Rubio share his insights on why we need biomarkers for Schizophrenia, why we don’t already have biomarkers for Schizophrenia, what’s necessary to bring biomarkers to the clinic and how today’s neuroimaging tools have significantly progressed the development of clinically applicable biomarkers.
Jose M. Rubio M.D., Ph.D.
- Institute for Behavioral Science, Feinstein Institute of Medical Research – Northwell Health, Manhasset, NY, USA
- Donald and Barbara Zucker School of Medicine at Hofstra University – Northwell Health, Hempstead, NY, USA
- Division of Psychiatry Research – Zucker Hillside Hospital – Northwell Health, 75-59 26, 3rd st, Glen Oaks, NY 11004, USA
Related content
Professors Shen-Yang Lim and Christoph Correll explore dopamine’s role in Parkinson’s disease and schizophrenia, discussing treatment evolution, side effects, and parallels between the disorders. Access more resources at Neurotorium.org.
Professors Christoph Correll and Gabriele Fischer discuss the challenges of managing co-occurring schizophrenia and substance use disorders, offering insights into this complex comorbidity.
The use of virtual reality in the treatment of severe mental illnesses